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Purpose
The aim of this study was to examine patterns of radiotherapy (RT) in Korean patients with
hepatocellular carcinoma (HCC) according to the evolving guideline for HCC established by
the Korean Liver Cancer Study Group-National Cancer Center (KLCSG-NCC).
Materials and Methods
We reviewed 765 patients with HCC who were treated with RT between January 2011 and
December 2012 in 12 institutions.
Results
The median follow-up period was 13.3 months (range, 0.2 to 51.7 months). Compared with
previous data between 2004 and 2005, the use of RT as a first treatment has increased
(9.0% vs. 40.8%). Increased application of intensity-modulated RT resulted in an increase
in radiation dose (fractional dose, 1.8 Gy vs. 2.5 Gy; biologically effective dose, 53.1 Gy10
vs. 56.3 Gy10). Median overall survival was 16.2 months, which is longer than that reported
in previous data (12 months). In subgroup analysis, treatments were significantly different
according to stage (p < 0.001). Stereotactic body RT was used in patients with early HCC,
and most patients with advanced stage were treated with three-dimensional conformal RT. 
Conclusion
Based on the evolving KLCSG-NCC practice guideline for HCC, clinical practice patterns of
RT have changed. Although RT is still used mainly in advanced HCC, the number of patients
with good performance status who were treated with RT as a first treatment has increased.
This change in practice patterns could result in improvement in overall survival.
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Introduction
Liver cancer is one of the leading primary cancers and the
main cause of death in Korea. The 5-year survival rates have
improved in liver cancer patients diagnosed from 2008 to
2012 compared with those diagnosed from 1993 to 1995.
However, the prognosis of liver cancer is still poor compared
to that of other cancer patients [1]. 
The Korean Liver Cancer Study Group (KLCSG) and the
National Cancer Center, Korea (NCC) developed a guideline
for the management of hepatocellular carcinoma (HCC) in
2003 [2]. This guideline provided recommendations for the
diagnosis and treatment of patients with newly diagnosed
HCC. The indications of radiotherapy (RT) were as follows:
(1) definitive aim: Child-Pugh (C-P) class A or B, tumor less
than two-thirds of the whole liver, and no extrahepatic
metastasis; (2) palliative aim: pain caused by tumor, tumor
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expected to rupture, portal vein tumor thrombosis, bile duct
obstruction due to tumor, or extrahepatic metastasis. 
After the development of this guideline, a national profile
of HCC patients who received RT between January 2004 and
December 2005 was reported [3]. Data from 10 institutions
were analyzed and 398 HCC patients were treated with RT.
Median age was 57 years and 85% of patients were male.
Three fourths of patients had C-P class A and the Eastern 
Cooperative Oncology Group (ECOG) performance status
was 0-1 in 234 patients (58.8%). Most patients (78%) were in
an advanced stage (stage III or IV), and 27 and 162 patients
had lymph node (LN) metastasis and portal vein thrombosis
(PVT), respectively. RT was used mainly as a salvage treat-
ment after the failure of other treatments and was performed
predominantly using three-dimensional conformal RT (3D
CRT). Median total and fractional dose were 45 Gy and 1.8
Gy, respectively. Median survival was 12 months and the
overall survival (OS) at 2 years was 27.9%. Tumor size, LN
metastasis, and biological effective dose (BED) were signifi-
cant factors of OS, and C-P class A was an additional signif-
icant factor in 326 patients treated with 3D CRT. Evaluation
of treatment outcome was available in 145 patients (36.4%).
After that, many studies regarding treatment outcome of
RT in Korean patients with HCC have been reported in
Korea. In 2009, the Clinical Practice Guideline for HCC was
revised by the KLCSG-NCC [4]. 
The aim of this study was to examine patterns of RT in 
patients with HCC in Korea according to the evolving guide-
line for HCC established by the KLCSG-NCC in 2009. The
secondary aim was to analyze treatment outcome and to find
out predictive clinical factors. 
Materials and Methods
Patients diagnosed with HCC by pathological confirma-
tion or radiological finding with an elevation of tumor
marker by KLCSG-NCC guideline and treated with RT for
HCC between January 2011 and December 2012 were eligible
for this study. RT was performed for primary HCC, PVT, or
regional LN metastasis. Exclusion criteria were presence of
distant metastasis, double primary cancer within 5 years, or
history of irradiation to the liver. Finally, we reviewed 765
patients with HCC who were treated with RT in 12 partici-
pating institutions. 
Data regarding patient, tumor, treatment, survival, and
treatment failure were collected. The modified International
Union for Cancer Control (mUICC) staging system that the
guideline recommended as a primary staging system was
used. Treatment data included RT technique, total radiation
Table 1. Patient and tumor characteristics
Characteristic
No. (%) 
(n=765)
Age, median (range, yr) 57 (24-86)
Sex
Male 641 (83.8) 
Female 124 (16.2) 
Viral type
B 596 (77.9) 
C 69 (9.0) 
B & C 5 (0.7) 
NBNC 86 (11.2) 
Other 9 (1.2) 
ECOG
0-1 714 (93.3) 
2-3 51 (6.7) 
C-P class
A 615 (80.4) 
B 128 (16.7) 
C 14 (1.8) 
Unknown 8 (1.0) 
Pre-RT treatment
No 312 (40.8) 
Yes 453 (59.2) 
mUICC stage
I 29 (3.8) 
II 111 (14.5) 
III 287 (37.5) 
IV 338 (44.2) 
Tumor sizea), median (range, cm) 6.5 (0-20.0)
No. of tumors 
Single 315 (41.3) 
Multiplicity 448 (58.7)
PVT
No 389 (50.8) 
Yes 376 (49.2) 
LN metastasis
No 667 (87.2) 
Yes 98 (12.8) 
Pre-RT tumor marker
AFP, median (range, IU/mL) 95.3 (0.3-2,922,754.0)
PIVKA-II, median 283.5 (7.0-176,595.0)
(range, mAU/mL)
NBNC, non-B non-C; ECOG, Eastern Cooperative Oncol-
ogy Group; C-P, Child-Pugh; RT, radiotherapy; mUICC,
modified International Union for Cancer Control; PVT,
portal vein thrombosis; LN, lymph node; AFP, alpha-
fetoprotein; PIVKA-II, protein induced by vitamin K 
absence-II. a)Tumor size: intrahepatic tumor size based on
modified Response Evaluation Criteria in Solid Tumors
Criteria.
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dose, fractional dose, and combination with other treatment
modality. Combination treatment was defined as a treatment
administered within 4 weeks of the start of RT or the end of
RT. Total radiation dose was converted to BED and the /
ratio was constrained to be 10 Gy.
Treatment failure was defined as progression of disease 
according to the modified Response Evaluation Criteria in
Solid Tumors and was categorized into infield and outfield
failures. Infield failure was defined as a treatment failure in
the RT field, and outfield failure included outfield-intrahep-
atic and extrahepatic failures. 
OS was calculated from the start day of RT to death, and
failure-free survival (FFS) was calculated from the start day
of RT to treatment failure. Survival was estimated using the
Kaplan-Meier method. Predictive factors of survival were 
analyzed using the Cox proportional hazard model, and
multivariate analysis was performed using stepwise regres-
sion. Age, tumor size, pre-RT -fetoprotein (AFP), and BED
were analyzed as continuous variables. Radiotherapy char-
acteristics according to stage were analyzed using the
Kruskal-Wallis test, and statistical analysis was performed
using SPSS ver. 20.0 (IBM Corp., Armonk, NY). 
Results
The median follow-up period for all patients was 13.3
months (range, 0.2 to 51.7 months). Patient and tumor char-
acteristics are shown in Table 1. The median age was 57 years
(range, 24 to 86 years), and 641 patients were male (83.8%).
Most patients (93.3%) had ECOG score 0-1, and 80.4% were
C-P class A; 82% of patients were diagnosed as mUICC stage
III or IV. Median tumor size was 6.5 cm (range, 0 to 20.0 cm),
and 376 patients (49.2%) had PVT. Before RT, the median
level of AFP was 95.3 IU/mL (range, 0.3 to 2,922,754.0
IU/mL), and the level of protein induced by vitamin K 
absence-II was 283.5 mAU/mL (range, 7.0 to 176,595.0
mAU/mL). Patients with treatment history before RT num-
bered 453 (59.2%), and transcatheter arterial chemoemboliza-
tion (TACE) or transcatheter arterial chemoinfusion (TACI)
was the most common treatment before RT (51.9%). 
The treatment characteristics of patients are shown in
Table 2. Tumors were included in the treatment volume in
84.4% of patients. Other patients were treated for PVT or
metastatic LN. RT was performed using 3D CRT (73.9%), 
intensity modulated radiotherapy (IMRT, 18.0%), or stereo-
tactic body radiotherapy (SBRT, 8.1%). The median fractional
dose was 2.5 Gy (range, 1.8 to 20.0 Gy), and the median BED
with 10 Gy of / was 56.3 Gy (range, 3.9 to 180.0 Gy). In
total, 733 patients (95.8%) completed the planned RT, and the
median BED (Gy10) in these patients was 58.5 Gy (range, 19.5
to 180.0 Gy). Combination with other treatment such as
TACE or chemotherapy was administered in 466 patients
(60.9%). 
The median OS for all patients was 16.2 months, and the
2-year survival rate was 37.7% (Fig. 1). In univariate analysis,
ECOG, C-P class, tumor size, number of tumors, LN metas-
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Table 2. Treatment characteristics
No. (%)Characteristic (n=765)
Treatment volume
Tumor 272 (35.6)
Tumor+PVT 347 (45.4)
Tumor+LN 12 (1.6)
Tumor+PVT+LN 14 (1.8)
PVT 63 (8.2)
PVT+LN 18 (2.4)
LN 39 (5.1)
RT technique
3D CRT 565 (73.9) 
IMRT 138 (18.0) 
SBRT 62 (8.1) 
Completion of planned RT
No 32 (4.2) 
Yes 733 (95.8) 
Combination treatment
No 299 (39.1)
Yes 466 (60.9) 
Radiation dose, median (range, Gy)
All patients (n=765)
Fractional dose 2.5 (1.8-20.0)
Total dose 45.0 (3.0-72.0)
BED (Gy10) 56.3 (3.9-180.0)
3D CRT (n=565)
Fractional dose 2.5 (1.8-6.0)
Total dose 45.0 (3.0-72.0)
BED (Gy10) 53.1 (3.9-96.0)
IMRT (n=138)
Fractional dose 2.5 (1.8-6.0)
Total dose 50.0 (30.0-72.0)
BED (Gy10) 68.8 (39.0-96.0)
SBRT (n=62)
Fractional dose 13.8 (5.0-20.0)
Total dose 45.0 (25.0-60.0)
BED (Gy10) 112.5 (37.5-180.0)
PVT, portal vein thrombosis; LN, lymph node; RT, radio-
therapy; 3D CRT, 3-dimensional conformal radiotherapy;
IMRT, intensity-modulated radiotherapy; SBRT, stereotac-
tic body radiotherapy; BED, biological effective dose.
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tasis, PVT, stage, pre-RT AFP, pre-RT treatment history,
BED, and RT technique were significant. ECOG, C-P class,
tumor size, number of tumors, LN metastasis, PVT, stage,
and pre-RT treatment history were significant factors in mul-
tivariate analysis (Table 3).  
Assessment of treatment outcome was available in 734 
patients (95.9%). Infield and outfield failure occurred in 235
(32.0%) and 547 (74.5%) patients, respectively, and the 2-year
FFS rate was 58.6% and 19.9% (Fig. 2). Univariate and multi-
variate analyses were performed for identification of predic-
tive factors of FFS. For infield FFS, C-P class, LN metastasis,
PVT, stage, BED, and RT technique were significant factors
in univariate analysis, and C-P class, stage, and BED were
still significant in multivariate analysis. Age, ECOG, C-P
class, tumor size, and PVT were significant factors of outfield
FFS, and BED showed borderline significance (p=0.053). 
In subgroup analysis according to stage (Table 4), RT tech-
niques were significantly different according to stage (p <
0.001). SBRT was used mainly in patients with early stage
HCC, and most patients with advanced stage HCC were
treated with 3D CRT or IMRT. Therefore, median fractional
dose and BED were different between stages and were
higher in early stage than advanced stage (p < 0.001). Com-
bination treatment with TACE or chemotherapy was fre-
quently administered in patients with advanced stage HCC.
OS rate at 2 years in each stage was 76.7%, 60.4%, 42.9%, and
22.0%, respectively (Fig. 3), and survival was significantly
different by stage (p < 0.001). The 2-year infield FFS rate was
84.1%, 71.8%, 63.8%, and 42.9%, respectively, and the outfield
FFS rate was 12.0%, 13.5%, 6.1%, and 4.9%.
Compared with the previous report, patient characteristics
including age, the ratio of sex, and the distribution of stage
were similar. Although RT was still considered in patients
with advanced HCC, the percentage of patients with good
performance status increased (ECOG 0-1, 58.8% vs. 93.3%),
and the use of RT as a first primary treatment (no pre-RT
treatment) has increased (9.0% vs. 40.8%). In terms of RT
technique, two-dimensional RT was not used in this study,
and use of IMRT increased (1.3% vs. 18.0%). Increase in
IMRT resulted in an increase in radiation dose (fractional
dose, 1.8 Gy vs. 2.5 Gy; BED, 53.1 Gy10 vs. 56.3 Gy10). OS was
improved in all patients (median, 12 months vs. 16.2 months;
2-year OS, 27.9% vs. 37.7%) and OS compared by stages also
showed improvement (I-II, 45.2% vs. 63.4%; III-IV, 24.0% vs.
33.9%). 
Discussion
In this study, we demonstrated that the pattern of radio-
therapy in treatment of HCC changed after revision of the
guideline in 2009. Similar to the previous guideline, RT is still
considered for advanced HCC. However, RT was more often
used as the first primary treatment option in patients with
good performance status. Use of IMRT has increased, result-
ing in increases in fractional dose and BED. The current 
patients showed better OS than those in the previous report.
Although the indication of RT was not significantly
changed in the 2009 guideline, the level of evidence of RT in
HCC increased from “no evidence or level 3” to “level 2."
This increased level of evidence was supported by many 
Korean reports regarding treatment outcome of RT for 
patients with HCC. Loco-regional treatment was considered
important and advancements in the RT technique and com-
bination with other treatment could result in the improve-
ment of treatment outcome, particularly in advanced HCC.
Based on many evidences and experiences, referring physi-
cians such as hepatologist or medical oncologist have grad-
ually recognized the role of RT as the first primary treatment
in patients with HCC with some learning curve period,
which appeared to affect the change in pattern of RT. RT in
treatment of HCC has changed from a salvage aim to a 
definitive aim, which might be associated with improved
survival.
In the Barcelona Clinic Liver Cancer guidelines, RT is not
recommended as a treatment option in patients with HCC
[5]. However, the application of RT in treatment of HCC has
increased, and the benefits of RT have been reported in many
studies. Some authors have suggested that the application of
Cancer Res Treat. 2017;49(1):61-69
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Fig. 1. Overall survival. During the follow-up period, 455
patients died. Median overall survival for all patients was
16.2 months and the 2-year survival rate was 37.7%. 
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Variable
Univariate Multivariate
Exp (B) 95% CI p-value Exp (B) 95% CI p-value
Overall survival
Age 0.994 0.986-1.003 < 0.181 - - -
Sex 0.924 0.726-1.175 < 0.517 - - -
ECOG 3.679 2.707-5.001 < 0.001 3.064 2.208-4.251 < 0.001
C-P class 3.371 2.752-4.129 < 0.001 2.651 2.120-3.316 < 0.001
Tumor size 1.089 1.067-1.111 < 0.001 1.057 1.032-1.083 < 0.001
No. of tumors 1.466 1.261-1.705 < 0.001 1.264 1.051-1.521 < 0.001
LN metastasis 2.255 1.779-2.858 < 0.001 1.746 1.332-2.291 < 0.001
PVT 1.931 1.613-2.310 < 0.001 1.337 1.077-1.658 < 0.001
Stage 1.822 1.613-2.058 < 0.001 1.320 1.114-1.564 < 0.001 
Pre-RT AFP 1.000 1.000-1.000 < 0.001 - - -
Pre-RT treatment 0.825 0.690-0.990 < 0.001 1.390 1.132-1.707 < 0.002 
BED 0.984 0.979-0.990 < 0.001 - - -
RT technique 0.456 0.314-0.660 < 0.001 - - -
Combination treatment 1.105 0.922-1.324 < 0.280 - - -
Infield failure-free survival
Age 0.998 0.986-1.010 < 0.697 - - -
Sex 0.927 0.655-1.313 < 0.670 - - -
ECOG 1.813 1.034-3.179 < 0.038 - - -
C-P class 1.740 1.237-2.447 < 0.001 1.590 1.115-2.267 < 0.010 
Tumor size 1.027 0.996-1.060 < 0.088 - - -
No. of tumors 1.057 0.850-1.314 < 0.620 0.706 0.545-0.914 < 0.008 
LN metastasis 1.804 1.262-2.579 < 0.001 - - -
PVT 1.894 1.462-2.454 < 0.001 1.295 0.972-1.726 < 0.077 
Stage 1.748 1.468-2.082 < 0.001 1.652 1.326-2.060 < 0.001
Pre-RT AFP 1.000 1.000-1.000 < 0.639 - - -
Pre-RT treatment 1.078 0.827-1.405 < 0.577 1.670 1.258-2.216 < 0.001
BED 0.977 0.969-0.986 < 0.001 0.986 0.977-0.995 < 0.003 
RT technique 0.416 0.237-0.729 < 0.002 - - -
Combination treatment 1.134 0.870-1.477 < 0.352 - - -
Outfield failure-free survival
Age 0.988 0.980-0.996 < 0.002 0.991 0.983-0.999 < 0.036 
Sex 0.920 0.735-1.153 < 0.470 - - -
ECOG 2.167 1.512-3.106 < 0.001 1.791 1.222-2.625 < 0.003
C-P class 1.735 1.388-2.168 < 0.001 1.510 1.184-1.925 < 0.001 
Tumor size 1.046 1.025-1.067 < 0.001 1.035 1.010-1.061 < 0.007 
No. of tumors 1.349 1.171-1.555 < 0.001 1.185 0.996-1.409 < 0.055 
LN metastasis 1.418 1.104-1.821 < 0.001 - - -
PVT 1.470 1.241-1.740 < 0.001 1.229 1.002-1.507 < 0.048 
Stage 1.359 1.223-1.509 < 0.001 1.142 0.985-1.325 < 0.078
Pre-RT AFP 1.000 1.000-1.000 < 0.001 - - -
Pre-RT treatment 1.086 0.914-1.290 < 0.348 1.349 1.075-1.692 < 0.010 
BED 0.990 0.986-0.995 < 0.001 0.995 0.989-1.000 < 0.053 
RT technique 0.653 0.478-0.892 < 0.007 - - -
Combination treatment 0.923 0.778-1.095 < 0.360 0.796 0.637-0.993 < 0.044
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; C-P, Child-Pugh; LN, lymph node; PVT, portal vein
thrombosis; RT, radiotherapy; AFP, -fetoprotein; BED, biological effective dose.
Table 3. Univariate and multivariate analysis
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RT according to the BCLC staging system could be used in
all stages of HCC [6-8]. In very early or early stage disease,
SBRT alone could be considered, and combination with
TACE is also possible if the patient is inoperable or not eligi-
ble for curative treatment such as surgery or radiofrequency
ablation (RFA). Combination with other treatment was rec-
ommended in intermediate or advanced stage. Palliative RT
for symptom relief was recommended for terminal patients. 
In 2014, the KLCSG-NCC revised the practice guidelines
for the management of HCC [9]. In addition to the indication
of the previous guideline, the revised guideline suggests that
external beam radiotherapy can be considered as an alterna-
tive treatment option in early stage disease. In patients with
early HCC who are ineligible for surgical resection, liver
transplantation, RFA, percutaneous ethanol injection, or
TACE and the tumor is far from a radiosensitive normal
organ, SBRT could be an effective treatment. 
The outcome of SBRT for HCC was reported in previous
studies [10,11]. SBRT showed high local control for inopera-
ble HCC patients and resulted in a survival benefit. Accord-
Cancer Res Treat. 2017;49(1):61-69
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Fig. 2. (A) Pattern of failure. Assessment of treatment outcome was available in 734 patients (95.9%). Infield and outfield
failure occurred in 235 (32.0%) and 547 (74.5%) patients. (B) Failure-free survival (FFS) for infield failure. Median FFS was
not reached and 2-year FFS rate was 58.6%. (C) FFS for outfield failure. Median FFS was 9.8 months and 2-year FFS was
19.9%.
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ing to a nationwide survey conducted in Korea, the applica-
tion of SBRT has increased, and the liver is a common treat-
ment site [12]. In this study, the percentage of patients treated
with SBRT was similar to that in a previous report, and SBRT
was used mainly as a salvage treatment for recurrent tumors
with early stage. Unfortunately, detailed data from previous
study could not be obtained for specific comparison of RT
dose. SBRT was introduced in the previous era of study and
has now become popular throughout the nation. It can be
postulated that dose of SBRT was not sufficient in the previ-
ous study period, and the experience and advancement of
the SBRT technique became available for more delicate treat-
ment, which could contribute to survival gain in early stage.
Combination treatment was administered in 466 patients
(60.9%) who were considered mainly in advanced stage
rather than early stage HCC. TACE or TACI was adminis-
tered in 41.9% of patients, and hepatic arterial infusional
chemotherapy (HAIC) was administered in 23.1% of pati-
ents. Radiotherapy following TACE is known to be effective
[13-15]. A prospective phase 2 multicenter study conducted
in Korea demonstrated that TACE plus RT is a safe and 
effective treatment in patients with unresectable HCC. Shim
et al. [15] reported that TACE+RT showed better survival
than TACE alone, particularly in patients with tumors  8 cm
in diameter. Concurrent chemoradiotherapy (CCRT) using
HAIC is a treatment option in locally advanced HCC [16,17].
Overall tumor response after CCRT was approximately 60%,
and response in both tumor and portal vein tumor thrombo-
sis showed significant correlation with improved survival.
Due to improvement in RT techniques, two-dimensional
conventional RT is no longer used, and the use of IMRT has
increased. Although the median total dose was not different
from that in the previous report, fractional dose and BED 
increased in the current study, possibly due to an increase in
IMRT. IMRT for HCC has shown a good response without
severe complications in several studies [18-20]. Yoon et al.
[19] compared treatment outcomes between patients with 
locally advanced HCC treated with 3D CRT and those
treated with IMRT by propensity score matching method.
Patients treated with IMRT showed better survival than
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Table 4. Treatment characteristics according to stage
Characteristic Stage I Stage II Stage III Stage IV p-value(n=29) (n=111) (n=287) (n=338)
RT technique
3D CRT 13 (44.8) 61 (55.0) 228 (79.4) 263 (77.8) < 0.001
IMRT 1 (3.4) 24 (21.6) 43 (15.0) 70 (20.7)
SBRT 15 (51.7) 26 (23.4) 16 (5.6) 5 (1.5)
Fractional dose (Gy) 7.0 (2.0-19.0) 3.5 (1.8-20.0) 2.5 (1.8-20.0) 2.5 (1.8-13.0) < 0.001
BED (Gy10) 79.2 (42.9-165.3) 65.3 (37.5-180.0) 56.0 (3.9-180.0) 53.1 (14.4-119.6) < 0.001
Completion of planned RT
No 0 ( 1 (0.9) 7 (2.4) 24 (7.1) 0.005 
Yes 29 (100) 110 (99.1) 280 (97.6) 314 (92.9)
Combination treatment
No 26 (89.7) 71 (64.0) 98 (34.1) 104 (30.8) < 0.001
Yes 3 (10.3) 40 (36.0) 189 (65.9) 234 (69.2)
Values are presented as number (%) or median (range). RT, radiotherapy; 3D CRT, 3-dimensional conformal radiotherapy;
IMRT, intensity-modulated radiotherapy; SBRT, stereotactic body radiotherapy; BED, biological effective dose.
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Fig. 3. Overall survival according to stage. Overall sur-
vival rates at 2 years in each stage were 76.7%, 60.4%,
42.9%, and 22.0%, respectively, and it was significantly dif-
ferent by stage (p < 0.001).
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those treated with 3D CRT, and RT modality was a signifi-
cant factor of OS [19]. Kim et al. [20], who reported the results
of simultaneous integrated boost-IMRT (SIB-IMRT) in 
patients with inoperable HCC, suggested that SIB-IMRT was
a feasible and safe treatment for patients with inoperable
HCC. However, there was no significant difference in sur-
vival or treatment failure between 3D CRT and IMRT in the
current study. Based on a retrospective multi-institutional 
review, it was thought to be due to the heterogeneity of 
patient and treatment characteristics. In 2015, the indications
of IMRT were expanded to treatment for patients with HCC,
and it is thought that the use of IMRT will further increase. 
Tumor size, LN metastasis, C-P class, and BED were sig-
nificant factors of OS in the previous report. Similarly,
ECOG, C-P class, tumor size, number of tumors, PVT, and
stage were significant factors of OS in the current study.
Tumor factors and host factors (performance status, liver
function) are important for survival outcome. BED was not
a significant factor of OS; however it was a significant factor
of infield failure. 
Although this study was not a complete enumeration sur-
vey and conducted in 12 institutions, most institutions that
treat a large number of HCC patients with RT were included
and nine of 12 institutions are included in both the previous
and current study. This study was based on a retrospective
review in multiple institutions; therefore, complete data 
regarding toxicity or quality of life could not be obtained.
However, evaluation of treatment outcome was available in
most patients (95.9%), while the previous study reported dis-
ease status in only one-third of all patients. The result of this
study does not represent the practice pattern of all HCC 
patients with regard to RT in Korea; however, it shows 
increased understanding among members of the hepatic 
oncologists society in terms of RT application, which expands
to the primary aim.
Further study examining changes in patterns of RT in HCC
is required after revision of the KLCSG-NCC guideline in
2014.
Conclusion
By increasing the level of evidence of RT in the KLCSG-
NCC guideline, clinical practice patterns of RT have
changed. RT is still used mainly in advanced HCC; however,
the number of patients with good performance status who
received RT as a first treatment has increased. This change
in practice patterns could result in improvement in OS.
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